You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

VACCINE DESIGN

Arexvy includes both an antigen component and an adjuvant system

Mechanism of Action

By combining the RSVPreF3 antigen with an adjuvant system (AS01E), AREXVY induces antigen-specific cellular immune response and neutralising antibodies that help protect against RSV-associated LRTD.1

Antigen icon and Shield icon Antigen icon and Shield icon

Abbreviations

LRTD=lower respiratory tract disease; RSV=respiratory syncytial virus; RSVPreF3=recombinant RSV glycoprotein F stabilised in the pre-fusion conformation.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

©2024 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.

PM-IE-RSA-WCNT-230002 | May 2024